The Pharmaceutical Journal
Vol 273 No 7314 p279
28 August 2004

This article
Reprint   Photocopy

  Acrobat Reader

News summary

New incontinence treatment

Patients with overactive bladder syndrome may benefit from a new incontinence treatment launched this week by Yamanouchi.

Solifenacin succinate (Vesicare) is a bladder selective anti-muscarinic agent for the symptomatic treatment of urge incontinence or increased urinary frequency and urgency. It is administered orally once daily and its maximum effect can be determined after a minimum of four weeks.


Notice-board p283